Results 21 to 30 of about 9,340 (184)

Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses

Respiratory Research, 2023
Introduction Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab.
Ayobami Akenroye, Tanawin Nopsopon, Laura Cho, Matthew Moll, Scott T. Weiss   +4 more
doaj   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications-An EAACI Task Force Report. [PDF]

Allergy
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Toppila-Salmi S, Reitsma S, Hox V, Gane S, Gevaert P, Maza-Solano J, Helevä A, Sulku I, Santala K, Kangasniemi I, Klimek L, Chaker A, Karavelia A, Rudenko M, Pfaar O, Van Gerven L, Ariana S, Schiappoli M, Lundberg M, Hagemann J, Eguíluz-Gracia I, Moreira A.   +21 more
europepmc   +2 more sources

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Heliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi, Masamitsu Eitoku, Akihito Yokoyama   +2 more
doaj   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Frontiers in Immunology, 2023
Introduction Clinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma ...
I. Pavord, F. Gardiner, L. Heaney, C. Domingo, R. Price, A. Pullan, J. Oppenheimer, G. Brusselle, H. Nagase, G. Chupp, E. Pizzichini, David Bañas-Conejero, P. Howarth   +12 more
semanticscholar   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source

Characteristics of new adult users of mepolizumab with asthma in the USA

BMJ Open Respiratory Research, 2021
Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ...
Pamela M McMahon, Ann Chen Wu, Emily Welch, Cheryl N McMahill-Walraven, Aziza Jamal-Allial, Mia Gallagher, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S Brown, Melissa K Van Dyke   +11 more
doaj   +1 more source

Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis. [PDF]

Int Forum Allergy Rhinol
Key Points Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.
Ramos ER, Satyavolu S, Miller AL, Scangas GA, Soler ZM, Schlosser RJ, Lin Y, Rathi VK.   +7 more
europepmc   +2 more sources

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

Farmacia Hospitalaria, 2019
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin
Manuel David Gil-Sierra, Leticia García-Mochón, Emilio Jesús Alegre-del Rey, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo   +4 more
doaj   +1 more source